Monique C.J. Hanse

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

Walter Taal, Hendrika M. Oosterkamp, Annemiek Walenkamp et al. · The Lancet Oncology · 2014 · 738 citations

Neuro-oncology, Oncology, Single-agent Bevacizumab +10

Transcriptome analysis reveals tumor microenvironment changes in glioblastoma

Youri Hoogstrate, Kaspar Draaisma, Santoesha A. Ghisai et al. · Cancer Cell · 2023 · 231 citations · Full text

Neuro-oncology, Glioma, Tumor Heterogeneity +13

Molecular Evolution of <i>IDH</i> Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study

Kaspar Draaisma, Aikaterini Chatzipli, Martin Taphoorn et al. · Journal of Clinical Oncology · 2019 · 110 citations

Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial

Lale Erdem‐Eraslan, Martin J. van den Bent, Youri Hoogstrate et al. · Cancer Research · 2016 · 98 citations · Full text

Recovery of Posterior Communicating Artery Aneurysm-Induced Oculomotor Palsy after Coiling

Monique C.J. Hanse, M.C.F. Gerrits, Willem Jan van Rooij et al. · American Journal of Neuroradiology · 2008 · 75 citations · Full text